Since proteasome inhibitors such as bortezomib and carfilzomib are in clinical use [13], knowledge on their potential to induce cell death in cancer cells that are highly resistant to Bax/Bak-dependent mitochondrial apoptosis might offer translational perspectives. This evidence concerns the gene BAK1 and cancer.